Trials / Completed
CompletedNCT03267732
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
A Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of AM0010 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
Detailed description
This is an open-label, single-center, phase 1 study designed to evaluate the pharmacokinetics in healthy adult participants after single and multiple subcutaneous injections of pegilodecakin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pegilodecakin | Pegilodecakin Alone |
Timeline
- Start date
- 2017-09-05
- Primary completion
- 2017-10-30
- Completion
- 2017-10-30
- First posted
- 2017-08-30
- Last updated
- 2019-04-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03267732. Inclusion in this directory is not an endorsement.